Business
Mesoblast treatment gets US panel’s key tick of approval – Sydney Morning Herald
The drug that Mesoblast has been trialling on some COVID-19 patients has just got the nod from a US regulator panel for treating children with severe responses to bone marrow transplants.
Stem cell treatment producer Mesoblast has recorded a significant win after the US FDA’s Oncologic Drugs Advisory Committee voted in favour of its flagship product for treating children with severe responses to bone marrow transplants.
The planned meeting of the US regulator had sent Mesoblast shares on a rollercoaster this week. The multi-billion company’s share price dropped more than 30 per cent in a single session on Tuesday after briefing papers released ahead of the meeting revealed the w…
-
General23 hours agoSearch underway for missing boat off South Australia’s Cape Jaffa
-
Noosa News23 hours agoQueensland coroner investigates ‘extremely unusual’ deaths of premature twin boys
-
Noosa News9 hours agoThe Best Things to Do in Brisbane This New Year’s Eve
-
General8 hours agoFour escape injury after jumping from three-storey unit on fire in Newcastle